eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2015
vol. 32
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia

Izabela Kupryś-Lipińska
,
Marta Kołacińska-Flont
,
Jerzy Marczak
,
Paweł Górski
,
Zofia Kurmanowska
,
Piotr Kuna

Postep Derm Alergol 2015; XXXII (6): 478–479
Online publish date: 2015/12/11
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Omalizumab is a monoclonal antibody raised against class E immunoglobulin (IgE), approved for the treatment of chronic severe (in the EU) or moderate-to-severe (in the USA) IgE-mediated asthma. Omalizumab is effective in reducing asthma exacerbations, hospitalizations and emergency visits due to exacerbations as well as in improving patients’ quality of life (QoL) [1–3].
Here we report on a 41-year-old man suffering from severe allergic asthma with systemic and airway eosinophilia, despite using high-dose systemic corticosteroids. The disease began at the age of 36 with cough, dyspnea and poor exercise tolerance. The therapy included high-dose inhaled corticosteroids (ICS) in combination with long-acting 2-agonists (LABA), antileukotriene antagonists and rescue short acting 2-agonists (SABA). From the beginning, the disease has been severe and uncontrolled. Since 2011, dyspnea had been so severe that the patient permanently received 16 mg of methylprednisolone per day. Reduction of this dose ended up with a loss of asthma control. Moreover, the patient underwent functional endoscopic sinus surgery, due to turbinate hypertrophy.
In 2012, the patient was referred to our Department for a thorough diagnostic assessment. A 2-week washout from oral corticosteroids (OCS) was performed. On admission, the patient complained of significant breathlessness, wheezing, persistent productive cough and substantial limitation of exercise capacity. Physical examination revealed soft vesicular sound with a prolonged expiratory phase, numerous wheezes and rhonchi. Spirometry showed severe airflow limitation (FEV1 = 1.47 l (36% of a normal value (N)), FVC = 4.15 l (88% N), FEV1%FVC = 35.42%); reversibility test with bronchodilator was negative. Skin prick tests were positive for house dust mites and Alternaria sp. A class 2 specific IgE level was determined for Alternaria sp. by ELISA.
The blood eosinophil count was significantly increased (EO = 1.7 × 103/µl – 15.9% of white blood cells). Bronchoscopy revealed thick secretions covering bronchi and a very high airway eosinophilia (EO = 56.2%), as measured in bronchoalveolar lavage. Additional tests excluded parasites and protozoans infection as well as hypereosinophilic syndrome.
The final diagnosis at discharge was persistent severe asthma associated with chronic rhinosinusitis.
The patient was deemed to qualify for omalizumab treatment but due to reimbursement problems he could...


View full text...
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe